Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenström macroglobulinemia

Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenström macroglobulinemia (WM), where bortezomib has been successfully tested in clinical trials. Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-targ...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Roccaro, Aldo M., Sacco, Antonio, Aujay, Monette, Ngo, Hai T., Azab, Abdel Kareem, Azab, Feda, Quang, Phong, Maiso, Patricia, Runnels, Judith, Anderson, Kenneth C., Demo, Susan, Ghobrial, Irene M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2010
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2875093/
https://ncbi.nlm.nih.gov/pubmed/20110419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-09-243402
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares